NCT01349855View on ClinicalTrials.gov

Repeated Dosing Study With a New Insulin Glargine Formulation and Lantus® in Patients With Type 1 Diabetes Mellitus

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

May 31, 2011

Study Completion Date

May 31, 2011

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Insulin glargine HOE901

Pharmaceutical form:solution for injection: new formulation and marketed formulation Route of administration: subcutaneous

Trial Locations (1)

Unknown

Investigational site number 276001, Neuss

Sponsors

Lead Sponsor

Sanofi
All Listed Sponsors
lead

Sanofi

INDUSTRY